ArticleThe Journal of international medical research2025
Krebs von den Lungen-6 as a potent indicator of the frequency of chronic obstructive pulmonary disease exacerbation.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo evaluate the potential of systemic Krebs von den Lungen-6 level in predicting acute exacerbations of chronic obstructive pulmonary disease.MethodsThis two-phase study included a derivation phase (January 2022 to December 2022) involving 156 patients with stable chronic obstructive pulmonary disease, in which optimal Krebs von den Lungen-6 thresholds were identified through multivariate modeling. Serum levels of Krebs von den Lungen-6 and surfactant protein D were analyzed for correlations with exacerbation frequency, Chronic Obstructive Pulmonary Disease Assessment Test score, modified British Medical Research Council score, forced expiratory volume in 1 second percent predicted, and forced expiratory volume in 1 second/forced vital capacity ratio. Prospective validation was performed in a separate cohort (January 2023 to December 2023, n = 121) stratified by Krebs von den Lungen-6 thresholds.ResultsKrebs von den Lungen-6 and surfactant protein D levels were significantly correlated with exacerbation frequency, Chronic Obstructive Pulmonary Disease Assessment Test, and modified British Medical Research Council scores and were inversely associated with forced expiratory volume in 1 second percent predicted and forced expiratory volume in 1 second/forced vital capacity ratio. Multivariate analysis identified Krebs von den Lungen-6, but not surfactant protein D, as an independent predictor of high-exacerbation phenotypes (≥2 events/year). In the validation phase, the high-Krebs von den Lungen-6 group (≥400.5 U/mL) exhibited significantly higher annual exacerbation rates than the low-Krebs von den Lungen-6 group after adjustment for baseline characteristics.ConclusionsSerum Krebs von den Lungen-6 at ≥400.5 U/mL is an independent risk factor for frequent exacerbations of chronic obstructive pulmonary disease. Its association with inflammatory markers and lung function decline suggests potential utility in personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.